false 0000907654 0000907654 2024-11-14 2024-11-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 14, 2024 

 

 Oruka Therapeutics, Inc.

(Exact name of Registrant as Specified in its Charter)

 

Delaware   000-22873   36-3855489
(State or other jurisdiction
of incorporation)		   (Commission File Number)   (IRS Employer
Identification No.)

 

855 Oak Grove Avenue

Suite 100
Menlo Park, California

   94025
(Address of principal executive offices)     (Zip Code)

 

Registrant’s telephone number, including area code: (650) 606-7910

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:  


Title of each class		   Trading Symbol(s)  
Name of each exchange on which registered
Common Stock, $0.001 par value   ORKA   The Nasdaq Global Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On November 14, 2024, Oruka Therapeutics, Inc. (the “Company”) held its Special Meeting of Stockholders (the “Special Meeting”). Set forth below is a brief description of each matter considered and voted upon at the Special Meeting, together with the final tally of the number of votes cast for or against, as well as the number of abstentions and broker non-votes as to each such matter. A more complete description of each matter is set forth in the Company’s definitive proxy statement for the Special Meeting filed with the Securities and Exchange Commission on October 18, 2024.

 

Proposal 1: Approval of Conversion of Series A Preferred Stock to Common Stock

 

The Company’s stockholders approved the issuance of shares of the Company’s common stock upon conversion of the Company’s Series A Non-Voting Convertible Preferred Stock, par value $0.001 per share, issued in September 2024. The tabulation of votes on this matter was as follows:

 

  Shares voted for: 30,598,476
  Shares voted against: 6,026
  Shares abstaining 1,089

 

There were no broker non-votes for this proposal.

 

Proposal 2: Approval of an Adjournment of the Special Meeting, if Necessary or Appropriate, to Solicit Additional Proxies

 

The Company’s stockholders approved an adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies. The tabulation of votes on this matter was as follows:

 

  Shares voted for: 29,294,720
  Shares voted against: 1,309,805
  Shares abstaining 1,066

 

There were no broker non-votes for this proposal.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

  Oruka Therapeutics, Inc.
     
By:

/s/ Paul Quinlan

  Name: Paul Quinlan
  Title:

General Counsel

Dated: November 18, 2024

 

 

 

v3.24.3
Cover
Nov. 14, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 14, 2024
Entity File Number 000-22873
Entity Registrant Name Oruka Therapeutics, Inc.
Entity Central Index Key 0000907654
Entity Tax Identification Number 36-3855489
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 855 Oak Grove Avenue
Entity Address, Address Line Two Suite 100
Entity Address, City or Town Menlo Park
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94025
City Area Code (650)
Local Phone Number 606-7910
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol ORKA
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Oruka Therapeutics (NASDAQ:ORKA)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024 Haga Click aquí para más Gráficas Oruka Therapeutics.
Oruka Therapeutics (NASDAQ:ORKA)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024 Haga Click aquí para más Gráficas Oruka Therapeutics.